Company news

AnaptysBio, Inc. news in 2023

AnaptysBio, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

November 26, 2023

Anaptys Named a BioSpace 2024 Best Places to Work Winner

November 6, 2023

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

November 1, 2023

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

October 10, 2023

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

October 8, 2023

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

October 8, 2023

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

September 17, 2023

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

September 11, 2023

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

August 6, 2023

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

July 30, 2023

AnaptysBio Announces Participation in Upcoming Investor Conferences

May 29, 2023

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

May 10, 2023

AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)

May 1, 2023

AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors

April 5, 2023

AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurr...

March 26, 2023

AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

February 28, 2023

AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference

February 26, 2023

AnaptysBio Announces Stock Repurchase Plan

January 12, 2023

AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies

January 4, 2023

Decks in 2023